Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ABBOTT LABORATORIES reported revenue of $44.33B, up 5.7% year over year. Operating margin was 18.2% and net margin 14.7%, on a free-cash-flow margin of 16.7% with capital expenditure at 4.9% of revenue. Every figure is computed directly from ABT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $44.33B | 18.2% | 14.7% |
| FY2024 | $41.95B | 16.3% | 31.9% |
| FY2023 | $40.11B | 16.2% | 14.3% |
| FY2022 | $43.65B | 19.2% | 15.9% |
| FY2021 | $43.08B | 19.6% | 16.4% |
How does ABT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PG · JNJ · ABBV · BMY · AMGN · LIN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.